Eisai Completes Rolling Submission of sBLA to FDA for LEQEMBI Approval

Eisai has finalized the rolling submission of its Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb, marketed under the brand name LEQEMBI in the United States. The company confirmed this milestone as part of its efforts to seek regulatory approval for the product.

The sBLA process allows companies to submit portions of their application as they are completed, expediting review timelines. Eisai’s submission marks a significant step in advancing LEQEMBI through regulatory channels. The FDA will now evaluate the application, which includes comprehensive data on safety, efficacy, and manufacturing processes related to lecanemab-irmb. This development follows ongoing research and clinical trials aimed at supporting LEQEMBI’s use in treating conditions specified by Eisai.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

Related posts:

Express Pharma’s May 2025 Issue Highlights Global Expansion of Indian Pharma & Biotech AI Enhances Drug Development and Biomarkers Refine Clinical Trials in Neurology and Oncology NYU Abu Dhabi Researchers Develop Brain Implant for Precise Drug Delivery to Multiple Regions Study Identifies Chromatin Modifier SMC1A as a Sex-Biased Factor in Systemic Lupus Erythematosus Development

Author

GOAI